Prevalence of hepatitis B in random Bulgarian blood samples – a single-site experience
DOI:
https://doi.org/10.2478/AMB-2023-0013Keywords:
Hepatitis B, HBsAg, anti-HBc, prevalence, BulgariaAbstract
The worldwide distribution of the HBV infection has usually been estimated by the prevalence of hepatitis B surface antigen (HBsAg) among the general population. Total antibodies for hepatitis B core antigen (anti-HBc) are the most important diagnostic marker for proving prior exposure to HBV. Aim: The aim of this study was to determine the prevalence of Hepatitis B virus (HBV) infection among Bulgarian population. Reliable epidemiologic data is needed to estimate the prevalence of Hepatitis B in order to determine the actual burden of the infection and to plan prevention and control measures. Materials and methods: A total of 2140 serum samples were tested for major serological markers of HBV (HBsAg and anti-HBc) for a period of two years (2018-2019). Results: We established an intermediate prevalence of HBsAg (5.1%) and high prevalence of anti-HBc (27%) among HBsAg negative individuals. Conclusion: In conclusion, the prevalence of Hepatitis B is much higher among those born before the introduction of universal hepatitis B vaccination in Bulgaria (1992).
References
Zampino R, Boemio A, Sagnelli C et al. Hepatitis B virus burden in developing countries. World J Gastroenterol. 2015;21(42):11941-53.
Hepatitis B – Annual epidemiological report for 2017. Stockholm: ECDC; 2019.
Shepard CW, Simard EP, Finelli L et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-25.
Argaw B, Mihret A, Aseff a A, et al. Seroprevalence of hepatitis B virus markers and associated factors among children in Hawassa City, southern Ethiopia. BMC infectious diseases. 2020;20(1):1-7.
Hatzakis A, Van Damme A, Alcoin A. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat, 2013;20(12):1-20.
Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14(1): 1-21.
Hwang EW, Cheung R. Global Epidemiology of hepatitis B virus (HBV) infection. North American J Med Sci, 2011;4(1): 7-13.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of agespecifi c HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-2219.
Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009;19:231-4.
Akinyemiju, T. et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional and national level. JAMA Oncol. 2017;3,1683.
Elgouhari HM, Abu-Rajab Tamimi TI, Carey WD. Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis. Cleve Clin J Med 2008;75(12): 881-9.
Todorova T, Tsankova G, Lodozova N. Hepatitis B infection in Eastern regions of Bulgaria. J of IMAB 2016;22(1):1033-1035.
Kevorkyan A, Teoharov P, Lernout T, et al. Prevalence of HBV and HCV among outpatients in the Plovdiv region of Bulgaria, 2010-2011. J Med Virol. 2015; 87: 401-406.
Chen CL, Yang JY, Lin SF, et al. Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol. 2015;63(2):354-63.
Gheorghe L, Csiki IE, Iacob S, et al. The prevalence and risk factors of hepatitis B virus infection in an adult population in Romania: a nationwide survey. Eur J Gastroenterol Hepatol. 2013 ;25(1):56-64.
Petrunov B, Kojouharova M, Teoharov P, et al. EU project interreg II: Seroepidemiology study of hepatitis C and B viral infections prevalence in Bulgaria and northern Greece. J Hepatol. 2002; 36: 138-139.
Teoharov P, Kevorkian A. Molecular epidemiology of HBV and HCV in Bulgaria. VHPB country meeting in Bulgaria. 23-25.03.2011; Sofi a. Bulgaria.
Raimondo G, Allain JP, Brunetto MR et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652-7.
Wang Q, Klenerman P, Semma N. Signifi cance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017;2(2):123-34.
Wu T, Kwok RM, Tran TT. Isolated anti HBc: the relevance ofhepatitis B core antibody: a review of new issues. Am J Gastroenterol 2017;112:1780-8.
Zobeiri M. Occult Hepatitis B: Clinical Viewpoint and Management. Hepat Res Treat. 2013; 2013: 259148.
Said Z. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17(15):1927-38.
Giudice CL, Martinengo M, Pietrasanta P, et al. Occult hepatitis B virus infection: a case of reactivation receiving immunosuppressive treatment for allogenic bone marrow transplantation. Blood Transfus. 2008;6(1):46-50.
Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: Molecular oncogenic potential of clear or occult infections. Eur J Cancer. 2010; 46: 2178-2186.
Yuen MF, Wong DK, Lee CK et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis 2011; 52(5): 624-32.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
